NASHVILLE, Tenn., Nov. 25, 2025 /PRNewswire/ — The Concinnity Company™ today announced that the REACH Trial and Coordinating Center (RCC) is using Cloud Concinnity® to strengthen oversight for Data Monitoring Committees (DMCs), steering committees, operations committees, and other academic research committees with the potential to extend efficiencies across Institutional Review Boards (IRBs) and additional teams.
Investigator-initiated trials, conducted by academic researchers, face unique challenges in coordinating diverse oversight bodies, managing sensitive data, and ensuring rigorous regulatory compliance for safety committees and DMCs due to the limited services available to manage this crucial aspect of a clinical trial. Cloud Concinnity provides a secure, Part 11 validated platform that brings structure, automation, and transparency to these processes.
This collaboration is already delivering measurable improvements:
“Our safety and data oversight committees are essential to advancing safe, ethical, and impactful clinical research. A platform that reduces the administrative burden investigators face when running their own clinical trials accelerates decision-making and allows our trial coordinating team to spend more time focusing on what matters most: delivering discoveries that improve patient outcomes.” —Alex Hall, DHSc, REACH Trial Co-Principal Investigator and Assistant Professor of Emergency Medicine and Neurosurgery at Emory University School of Medicine
“The REACH trial investigators are at the forefront of academic research. They’re setting a benchmark for how investigator-initiated trials and academia can accelerate innovation while maintaining the highest standards of regulatory compliance.” — Nancy Falls, CEO, The Concinnity Company
About The Concinnity Company
The Concinnity Company is the creator of Cloud Concinnity, a secure, 21 CFR Part 11 validated process integration and automation platform purpose-built for clinical trial oversight and broadly applicable to any workflow-driven process that requires repeatability, scalability, consistency, and compliance.
Cloud Concinnity automates, orchestrates, and connects complex business processes that span clinical functions. It provides a high degree of no-code configurability, enabling organizations to design flexible workflows for high-level users who must collaborate across functions, complete with regulatory-grade collaboration tools and capabilities.
The result is greater efficiency, speed, transparency and risk mitigation—so treatments can reach patients faster and at lower cost. The Concinnity Company team is dedicated to harnessing the power of process, innovation, and smart technology to create a stronger, healthier world. For more information, visit theconcinnitycompany.com.
About the REACH Trial
The Rapid Evacuation and Access of Cerebral Hemorrhage (REACH) Trial—sponsored by Emory University—is a medical research study aimed at finding better ways to treat people who have had a specific type of stroke called an intracerebral hemorrhage. The RCC creates the infrastructure and processes to design, conduct, implement, and manage the REACH Trial and Registry across more than 60 sites throughout the United States. For more information about the REACH Trial visit https://clinicaltrials.gov/study/NCT06870812.
Media Contact
405421@email4pr.com
(615) 988-1501
SOURCE The Concinnity Company
LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the…
A summary of the current discussions in consumer health and wellness on the topic of…
LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope…
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal…